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Abstract
The coagulation system is characterized by the sequential and highly localized activation of a series of serine proteases,
culminating in the conversion of fibrinogen into fibrin, and formation of a fibrin clot. Here we show that C-terminal peptides
of thrombin, a key enzyme in the coagulation cascade, constitute a novel class of host defense peptides, released upon
proteolysis of thrombin in vitro, and detected in human wounds in vivo. Under physiological conditions, these peptides
exert antimicrobial effects against Gram-positive and Gram-negative bacteria, mediated by membrane lysis, as well as
immunomodulatory functions, by inhibiting macrophage responses to bacterial lipopolysaccharide. In mice, they are
protective against P. aeruginosa sepsis, as well as lipopolysaccharide-induced shock. Moreover, the thrombin-derived
peptides exhibit helical structures upon binding to lipopolysaccharide and can also permeabilize liposomes, features typical
of ‘‘classical’’ helical antimicrobial peptides. These findings provide a novel link between the coagulation system and host-
defense peptides, two fundamental biological systems activated in response to injury and microbial invasion.
Citation: Papareddy P, Rydenga ˚rd V, Pasupuleti M, Walse B, Mo ¨rgelin M, et al. (2010) Proteolysis of Human Thrombin Generates Novel Host Defense
Peptides. PLoS Pathog 6(4): e1000857. doi:10.1371/journal.ppat.1000857
Editor: Ralph R. Isberg, Tufts University School of Medicine, United States of America
Received December 15, 2009; Accepted March 15, 2010; Published April 22, 2010
Copyright:  2010 Papareddy et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This research was supported by grants from from the Swedish Research Council (projects 2009-3378 and 2006-4469), the Marianne and Marcus
Wallenberg, Welander-Finsen, Crafoord, O ¨sterlund, and Kock Foundations, DermaGen AB, and The Swedish Government Funds for Clinical Research (ALF). The
funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: Drs. Schmidtchen and Malmsten have shares in DermaGen AB and XImmune AB, companies involved in the therapeutic development of
peptides for topical and systemic use, respectively.
* E-mail: artur.schmidtchen@med.lu.se
Introduction
The innate immune system, largely based on antimicrobial
peptides, provides a first line of defense against invading microbes
[1,2,3,4,5]. During recent years it has become increasingly evident
that many cationic and amphipathic antimicrobial peptides, such
as defensins and cathelicidins, are multifunctional, also mediating
immunomodulatory roles and angiogenesis [6,7,8], thus motivat-
ing the recent and broader definition host defense peptides (HDP)
for these members of the innate immune system. The family of
HDPs has recently been shown to encompass various bioactive
peptides with antimicrobial activities, including proinflammatory
and chemotactic chemokines [9], neuropeptides [10], peptide
hormones [11,12], growth factors [13], the anaphylatoxin peptide
C3a [14,15], and kininogen-derived peptides [16,17,18].
The coagulation cascade represents a fundamental host defense
system activated in response to injury and infection [19,20].
Through a series of cascade-like proteinase activation steps,
thrombin is formed, leading to fibrinogen degradation and clot
formation [20]. In addition, thrombin has other physiologic
functions in hemostasis; i.e., mediating clot stabilization by
activation of TAFI and activation of transglutaminase (FXIII),
providing anticoagulant and antifibrinolytic activities in complex
with thrombomodulin, and causing platelet aggregation due to
PAR cleavage [19,20]. Moreover, thrombin elicits numerous
cellular responses, including increased CAM expression and
growth factor and cytokine release by endothelial cells, as well as
growth stimulation of both smooth muscle and fibroblast cells [20].
These pivotal functions of thrombin in host defense, its ubiquitous
occurrence in blood and in fibrin networks, the high evolutionary
conservation of the enzyme, as well as presence of an amphipathic,
cationic and helical C-terminus in the protein [19], made us raise
the question whether thrombin could constitute a source of HDPs
released at sites of wounding and infection. Our results indeed
show that C-terminal peptides of thrombin constitute a previously
undisclosed and significant class of HDPs, generated in humans
during wounding and with therapeutic potential against infection
and septic shock.
Results
Proteolysis of prothrombin and thrombin generates
antimicrobial activity
To test the hypothesis that prothrombin or its activated forms
may generate antimicrobial peptides upon fragmentation, we
incubated human prothrombin and thrombin with neutrophil
elastase, a major neutral protease released by leukocytes during
blood coagulation and inflammation or in response to bacterial
products such as endotoxins. Earlier studies have shown that
neutrophil elastase acts on proteinase-sensitive regions in human
PLoS Pathogens | www.plospathogens.org 1 April 2010 | Volume 6 | Issue 4 | e1000857thrombin, generating smaller fragments [21]. As judged by the
RDA assays (Figure 1A), digestion of the proteins yielded
antimicrobial activity already after 5 min of incubation with the
enzyme. In contrast, the intact mother proteins were inactive. The
activity following proteolysis was still observed after several hours
of incubation, suggesting the presence of relatively stable
intermediates. Noteworthy, the maximum observed inhibition
zones were similar in size to those generated by the classical
antimicrobial peptide LL-37. Analysis by SDS-PAGE (Figure 1B)
showed that the degradation generated several low molecular
weight fragments in the range of 5–15 kDa. In spite of the known
amidolytic properties of thrombin, no detectable antimicrobial
activity was detected after prolonged incubation of the enzyme
form alone (not shown). The observation that the zymogen as well
as the activated forms generated similar activities, suggests that the
antimicrobial epitopes localize to regions in the active enzyme
after R271 (prothrombin numbering).
Structure-based screening for identification of
antimicrobial epitopes
In order to identify possible antibacterial peptide regions of
prothrombin/thrombin, overlapping peptide sequences compris-
ing 20mers (Figure 2A) were synthesized and screened for
antibacterial activities against the two test bacteria E. coli and P.
aeruginosa. Properties common for most antimicrobial peptides
include minimum levels of cationicity, amphipathicity, and
hydrophobicity [5]. Taking these structural prerequisites into
account, additional peptides comprising regions of high net charge
and/or presence of amphipathic helical regions, such as those
encompassing the C-terminus, were selected and synthesized
(Figure 2A). The experiments showed that particularly peptides
derived from the C-terminal region (peptides 45–48) were
antimicrobial, although other active peptides were also identified
(eg. 9 and 31) (Figure 2B). However, at high ionic strength (0.1 M
NaCl), only the C-terminal peptides retained their antimicrobial
activity against E. coli as well as P. aeruginosa (Figure S1)
demonstrating that only this region, characterized by a high
relative hydrophobicity (mHrel), positive net charge (znet=+2 for
Author Summary
Wounding of the skin and other epithelial barriers
represents an ever-present challenge and poses a potential
threat for invasive infection and sepsis. Therefore, it is not
surprising that evolutionary pressure has maintained and
developed multiple host defense systems, involving initial
hemostasis and fibrin formation, and the subsequent
action of multiple proteins and peptides of our innate
immune system. In humans, the coagulation pathways and
those mediating innate immune responses to infections
have so far been seen as separate entities. This view is
challenged by the present study, which discloses novel
host defense functions of C-terminal peptides of thrombin,
a key enzyme in the coagulation cascade. The thrombin-
derived peptides, which are detected in human wounds
and fibrin, effectively kill microbes by membrane lysis, but
also exert potent immunomodulatory and anti-endotoxic
functions. Importantly, these peptides protect against P.
aeruginosa sepsis, as well as lipopolysaccharide-induced
shock in animal models. Thus, from the perspective of
wounding and infection, thrombin, after fulfilling its
primary function by generating a first line of defense,
the fibrin clot, serves an additional role by the generation
of antimicrobial and anti-endotoxic host-defense peptides.
Figure 1. Generation of antimicrobial peptides by degradation of prothrombin and thrombin. (A) Degradation of the proteins was
performed at 37uC for the indicated time periods. RDA was performed in low-salt conditions using E. coli as test organism. Each 4 mm-diameter well
was loaded with 6 ml of the solution (corresponding to 3.6 mg protein). The bar diagrams indicate the diameter of the zones of clearance obtained (in
mm). The inset visualizes the results obtained with prothrombin. C, buffer; NE, neutrophil elastase only. LL-37 (100 mM) was included for comparison.
(B) Intact prothrombin (PT) and thrombin (T), and cleavage products from the different incubations with neutrophil elastase (NE, indicated above)
were analyzed by SDS-PAGE (16.5% Tris-Tricine gel). The gels are overloaded (12 mg) in order to visualize generation of fragments of low molecular
masses. Rightmost two lanes show PT and T proteins at 2 mg.
doi:10.1371/journal.ppat.1000857.g001
Host Defense Peptides of Human Thrombin
PLoS Pathogens | www.plospathogens.org 2 April 2010 | Volume 6 | Issue 4 | e1000857the most active C-terminal peptides) (Figure 2B) and amphipathi-
city (Figure 2C), features typical of classical antimicrobial peptides
[1,2,3,4], may generate peptides active against bacteria at
physiologic conditions. Corresponding to the antimicrobial
activities observed above, only peptides derived from the C-
terminal part significantly bound to E. coli LPS (Figure 2D).
Figure 2. Activities of peptides derived from prothrombin. (A) Sequence of prothrombin and overlapping peptides (indicated by numbers).
In addition to the regular overlapping peptides, peptide regions of high net charge, and/or content of predicted helical regions (Agadir; http://www.
embl-heidelberg.de/Services/serrano/agadir/agadir-start.html) were selected. Peptides described in subsequent experiments are also indicated;
GKY25, VFR17, and the major ,11 kDa peptide (amino acids 527–622). (B) Overlapping peptides of prothrombin were analyzed for antimicrobial
activities against E. coli. The inhibitory zones, relative hydrophobic moment (mHrel) as well as net charge of respective peptides (only active peptides
are numbered) are indicated in the 3-D graph. Peptides showing antimicrobial activity are also indicated by red color in (A). For determination of
antibacterial activities, E. coli (4610
6 cfu) was inoculated in 0.1% TSB agarose gel. Each 4 mm-diameter well was loaded with 6 ml of peptide (at
100 mM). The zones of clearance correspond to the inhibitory effect of each peptide after incubation at 37uC for 18–24 h (mean values are presented,
n=3). (C) Helical wheel representation of the C-terminal peptide VFR17. The amino acids are indicated. (D) LPS-binding activity of the prothrombin-
derived peptide sequences. Peptides (5 mg) were applied to nitrocellulose membranes followed by incubation in PBS (containing 2% bovine serum
albumin) with iodinated (
125I)-LPS. Only peptides from the C-terminal part of prothrombin demonstrated significant binding to LPS. (E) Molecular
model of thrombin. The peptides GKY25 (green-orange, indicated in Figure 2A) and VFR17 (orange, peptide 48 in Figure 2A) are indicated in the
crystal structure of human thrombin (PDB code 1C5L). (F) Activities of prothrombin (PT), thrombin (T), GKY25 and VFR17 on E. coli ATCC 25922. In
viable count assays GKY25 and VFR17 displayed significant antibacterial activities. 2610
6 cfu/ml of bacteria were incubated in 50 ml with proteins and
peptides at a concentration of 3 and 6 mM, respectively.
doi:10.1371/journal.ppat.1000857.g002
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possibly be attributed to their high molecular weight (compromis-
ing diffusion during the assay), the antibacterial results above were
further substantiated by matrix-free viable count assays. The
results demonstrated that in contrast to the holoproteins, the
selected model peptides VFR17 (Figure 2A; peptide 48) and the
longer 25mer peptide GKY25 (indicated in Figure 2A) from the C-
terminal part of the enzyme (both peptides indicated by colors in
the 3D model of thrombin; Figure 2E), demonstrated significant
antibacterial activity (Figure 2F), thus corroborating the RDA
assays above (Figure 1A and Figure 2B). In conclusion, LPS-
binding and antimicrobial data, combined with structural and
biophysical considerations clearly indicate a pivotal role of
Thrombin-derived C-terminal Peptides, in the following text
denoted ‘‘TCP’’, for mediating the antimicrobial activity.
Definition of low molecular weight fragments generated
by degradation of thrombin
In parallel to the above structure-based screening approach,
studies were undertaken to identify active fragments generated
after subjection of thrombin to neutrophil elastase. RP-HPLC
separation of elastase-digested thrombin, followed by antibacterial
assays using E. coli identified several antibacterial peptide fractions
(Figure 3A). Combined analyses using MALDI-TOF, ESI-MS/
MS, and N- and C-terminal sequencing of fraction no. 38, which
contained the majority of the activity comprising peptides active in
high salt, unambiguously identified a major 11041 Da fragment
comprising the C-terminal 96 amino acids of thrombin (amino
acid 527–622, predicted pI 8.4, indicated in Figure 2A).
Correspondingly, SDS-PAGE identified one single peptide of
,11 kDa, that contained the C-terminal epitope, as shown by
immunoblot analysis using polyclonal antibodies against the C-
terminal peptide VFR17 (Figure 3A, rightmost upper panel). Gel
overlay assays demonstrated that the major antimicrobial peptide
of fraction 38 corresponded to one major active peptide, also
identified in neutrophil elastase-digested thrombin (Figure 3A,
rightmost lower panel), showing significantly lower mobility when
compared to the C-terminal peptide GKY25, thus reflecting its
higher molecular mass. Interestingly, MALDI-TOF and ESI-MS/
MS of fraction no. 30 identified the peptide HVFRLKKWIQK-
VIDQFGE, described in the previous in vitro screening experi-
ments (Figure 2A and B, peptide 47), as well as a shorter 16 aa
long variant (Figure 3A, FRLKKWIQKVIDQFGE), both pep-
tides from the C-terminus of thrombin. The analyses of the less
hydrophobic material (fractions 20 and 21) yielded several low
molecular weight fragments corresponding to internal, and
cationic, sequences of low hydrophobicity and amphipathicity,
matching antibacterial regions identified by the previous 20-mer
screening (Table S1 available online and Figure 2A). Taken
together, these results showed that neutrophil elastase generates
antimicrobial TCPs, of which the major forms comprise a
,11 kDa fragment of 96 amino acids, but also smaller fragments
from the distal helical and amphipathic terminus.
Thrombin-derived C-terminal fragments are generated
by human and bacterial proteinases
During inflammation, neutrophils release a multitude of
enzymes, which could have activity on either thrombin or its
proform. Therefore, thrombin was incubated with supernatants
from activated neutrophils and the material analysed for
antimicrobial activity and generation of TCPs. Indeed, antimi-
crobial activity was found upon proteolysis, while immunoblotting
identified several TCPs of similar molecular weights as those
generated by neutrophil elastase alone (Figure 3B). Similar
fragments (Figure 3C) and corresponding antimicrobial activity
(Figure 3D) were also detected when prothrombin was subjected to
neutrophil elastase, cathepsin G as well as the bacterial
thermolysin-like proteinase of Pseudomonas aeruginosa, lasB (also
denoted P. aeruginosa elastase) [22]. Interestingly, low molecular
weight peptides (,3–4 kDa), generated by the latter P. aeruginosa
enzyme, co-migrated with the model peptide GKY25 (Figure 3C).
These results demonstrated that both human and bacterial
enzymes may generate TCPs, irrespective of the activation state
of prothrombin.
C-terminal thrombin peptides are generated ex vivo and
in vivo and are protective against infection
Prothrombin, as many other proteins in plasma, is under
meticulous control by antiproteinases in the normal state,
preventing its activation and/or degradation. Therefore, we
hypothesized that favorable environments promoting TCP
formation should comprise i) localisation as well as concentration
of thrombin, and ii) local release of enzymes, such as neutrophil
elastase or bacterial proteinases. These environments are typical of
sites of injury and infection, such as skin wounds, comprising
thrombin activation, fibrin formation, bacterial colonization or
infection, and subsequent neutrophil influx. Earlier studies have
shown that thrombin binds to fibrin clots, and that fibrin acts as a
reservoir for active thrombin [23]. Furthermore, human neutro-
phils release elastase during clotting, and neutrophils also
penetrate fibrin [21]. Bacteria, such as S. aureus and P. aeruginosa
frequently colonize and infect skin wounds, accompanied by
excessive proteolysis and activation of neutrophils [24,25]. Given
this, the production of TCPs in fibrin, as well as in sterile or
infected biological fluids and wounds was investigated. The results
showed that TCPs were formed when fibrin clots were subjected to
neutrophil elastase in vitro (Figure 4A). Furthermore, a similar
,11 kDa fragment was detected in fibrin ‘‘slough’’ from a patient
with a non-infected chronic venous leg ulcer, indicating that TCPs
can be found in fibrin in vivo (Figure 4A). Analogous results,
showing rapid formation of TCPs, were obtained using human
plasma subjected to proteolysis by neutrophil elastase, thus
simulating the high elastase activity observed during wounding
(Figure 4B). Importantly, TCPs were also identified in wound fluid
from patients post-surgery, as well as in wound fluid from patients
with chronic (non-infected) venous leg ulcers (Figure 4B). The
latter wounds are always colonized by bacteria such as S. aureus
and P. aeruginosa [24].
Next, a series of experiments were performed in order to study
the physiological role of TCPs in relation to bacterial infection.
First, initial experiments showed that immunoreactive thrombin
fragments, including the ,11 kDa TCP peptide, are proteolyti-
cally generated and exclusively bind to bacteria during P. aeruginosa
infection of plasma and in presence of fibrin (Figure S2A). FACS
analysis utilizing antibodies against the C-terminal part of
thrombin showed that TCPs, either occurring in wound fluid
from acute wounds, or generated in human plasma during P.
aeruginosa infection, bind to the bacteria similarly to the above
described antibacterial C-terminal peptide GKY25 (Figure 4C).
Similar results were obtained using S. aureus (Figure S2B). Second,
electron microscopy studies employing gold-labeled antibodies
demonstrated that TCPs are predominantly associated with
bacterial surfaces ex vivo and in vivo. Thus, P. aeruginosa grown in
plasma or acute wound fluid exhibited disintegrated areas as
shown by ejected cytoplasmic material and membrane blebs
(Figure 4D, see P and AWF). Furthermore, C-terminal epitopes of
thrombin were found particularly in association with these
Host Defense Peptides of Human Thrombin
PLoS Pathogens | www.plospathogens.org 4 April 2010 | Volume 6 | Issue 4 | e1000857Figure 3. Identification of antibacterial regions of thrombin and prothrombin. (A) RP-HPLC separation of thrombin digested with neutrophil
elastase. The bars indicate the antibacterial activity of the fractions in low (gray) as well as high salt conditions (black). Fraction 30 (lower left)c o n t a i n e d
two peaks of masses 2034.78 and 2270.88, perfectly matching the indicated sequences obtained after ESI-MS/MS analysis. Fraction 38 was analyzed by
MALDI-MS, and subsequently by ESI-MS. The ESI-MS analysis identified a dominant mass of 11041 corresponding to the 96-amino acid long peptide
N527-E622 (indicated in Figure 2A) with two intact disulphide bridges. A minor mass corresponding to V528-E622 was also detected by ESI-MS/MS. N-
and C-terminal sequencing yelded NLPI and EGFQ, respectively. The rightmost insets illustrate the ,11 kDa peptide analysed by SDS-PAGE and stained
for protein (stain), or after immunoblot (blot), and below, the peptide (F38) was analyzed by gel-overlay for detection of antibacterial activity. The activity
of F38 was identical to the major clearing zone generated by elastase-digested thrombin (T+NE). Right arrow indicates the position of clearing zone
generated by the peptide GKY25. The gel was run top to bottom. Finally, peptides of fractions 20–21 were predicted using the FINDPEPT tool (www.
expasy.org/tools/findpept.html) (Table S1). (B) Degradation of thrombin by neutrophil supernatants generates antibacterial activity in RDA (upper inset).
RDA was performed in low-salt conditions. E. coli (4610
6 cfu) was used as test organism. Each 4 mm-diameter well was loaded with 6 mlo fm a t e r i a l( C ,
supernatant only; T, thrombin only; T+NS; thrombin incubated for 30 and 180 min respectively, with neutrophil supernatants). The digests were analysed
by SDS-PAGE (16.5% Tris-Tricine gels) and immunoblotting with antibodies against VFR17 (lower panel). (C) Prothrombin was digested with the enzymes
as indicated for 3 h, and analyzed by SDS-PAGE (16.5% Tris-Tricine gels) and immunoblotting using antibodies against VFR17 (NE, neutrophil elastase;C G ,
cathepsin G; PAE, P. aeruginosa elastase). (D) RDA results of prothrombin digested with cathepsin G (CG) and P. aeruginosa elastase (PAE) for different
time periods. VFR17 and LL-37 (10 mM) are shown for comparison.
doi:10.1371/journal.ppat.1000857.g003
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PLoS Pathogens | www.plospathogens.org 5 April 2010 | Volume 6 | Issue 4 | e1000857Figure 4. Thrombin-derived C-terminal peptides, their presence and antimicrobial effects ex vivo and in vivo. (A) Fibrin clots were
produced from human plasma and incubated with neutrophil elastase for the indicated time periods (Fibrin), or obtained from a patient with a
venous, non-infected, chronic ulcer (PF), extracted, and analyzed by immunoblotting using polyclonal antibodies against the thrombin C-terminal
peptide VFR17. (B) Human plasma, incubated with neutrophil elastase for the indicated time periods (Plasma, left panel), acute wound fluid (patients
1–2, AWF, middle panel), or wound fluid from patients with chronic ulcers (patients 1–6, CWF, right panel) was analysed by Western blot using
polyclonal antibodies against the thrombin C-terminal peptide VFR17. (C) Flow cytometry analysis of binding of C-terminal thrombin epitopes to P.
aeruginosa bacteria. Bacteria were incubated for 4 h with control plasma (P), human plasma depleted of prothrombin (DP), depleted plasma
supplemented with the peptide GKY25, or, acute wound fluid (AWF). Binding of C-terminal epitopes to the bacteria was detected using primary
antibodies against the C-terminal epitope VFR17 followed by addition of FITC-labeled secondary antibodies. (D) Visualization of binding and
membrane damage by TCPs. P. aeruginosa bacteria were incubated ex vivo with human plasma (P), acute wound fluid (AWF), or wound fluid from a
chronic leg ulcer (CWF), or visualized in vivo in fibrin slough (CWS) derived from a patient with a chronic ulcer infected by S. aureus. Arrows in P, AWF,
and CWF point to damaged bacterial membranes. Coccoid bacteria (indicated by an arrow in CWS) show extensive binding of antibodies directed
against the C-terminal peptide VFR17 (negative and positive bacterial controls, and additional material are found in Figure S3 and S4). (E) TCPs inhibit
bacterial growth in human plasma. Control plasma (P), plasma depleted of prothrombin (DP), depleted plasma supplemented with either
prothrombin (DP+PT), or GKY25 (DP+GKY25) (PT and GKY25 at 1.5 mM), or control AWF or depleted AWF (D-AWF), were inoculated with P. aeruginosa
bacteria under similar conditions as in (C–D). The multiplication factors at various time points are given. After incubation, CFUs were determined by
plating. Experiments were repeated three times and a representative experiment is shown. (F) The thrombin C-terminal peptide GKY25 significantly
increases survival. Mice were injected i.p. with P. aeruginosa bacteria, followed by subcutaneous injection of GKY25 or buffer only, after 1 h. The
injections were repeated after 24 hours. Treatment with the peptide significantly increased survival (n=10 for controls and treated, p=0.002). (G)
Host Defense Peptides of Human Thrombin
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aeruginosa with wound fluid derived from patients with chronic
ulcers (Figure 4D, CWF), as well after incubating the bacteria with
the C-terminal thrombin peptide GKY25 (Figure S3). Bacteria
grown in plasma or acute wound fluid supplemented with heparin
(shown to block the antimicrobial effects of the two C-terminal,
heparin-binding peptides of thrombin described above, GKY25
and VFR17) were similar to the control bacteria, and did not
exhibit either binding of TCPs or membrane damage (Figure S3).
Additionally, analysis of fibrin slough from a patient with a chronic
ulcer infected with P. aeruginosa and S. aureus, identified multiple
coccoid bacteria both extracellularly and inside phagocytes
(Figure 4D, CWS; Figure S4), that all displayed significant binding
of immunogold antibodies, demonstrating the existence of TCPs at
bacterial surfaces in vivo in fibrin from human wounds. Figure 4E
(upper panel) further shows that the growth of P. aeruginosa is
significantly enhanced in plasma depleted of prothrombin, when
compared with native control plasma. Furthermore, addition of
physiological concentrations of prothrombin, or the peptide
GKY25 (at 1.5 mM, equivalent to the physiological prothrombin
concentration), restored the suppressive effect of plasma on
bacterial growth. Acute wound fluid depleted of thrombin and
C-terminal fragments also showed increased growth of P. aeruginosa
when compared with the control (Figure 4E, lower panel). Similar
results were obtained with S. aureus (Figure S2C). Taken together,
these results, and given the above findings on the generation and
binding of TCPs to bacteria ex vivo and in vivo, unequivocally
demonstrate a direct link between occurrence of TCPs and
suppression of bacterial growth in plasma.
Further experiments with the model C-terminal peptide
GKY25, exhibiting antibacterial activities similar to the endoge-
nously produced C-terminal peptide HVF18 (peptide 47,
Figure 2A), were employed in order to further study a
physiological, as well as therapeutic role of TCPs. The MIC-
levels of GKY25, according to standard NCSLA-protocols, were
comparable to, and in some cases lower than, those observed for
LL-37 and omiganan (Table S2 available online). Since the latter
is a highly active and broad-spectrum designed antimicrobial
peptide now in Phase III clinical studies, the data on GKY25 also
implied a possible therapeutic role for TCPs. Initial studies
revealed no significant permeabilizing effects of GKY25 on human
erythrocytes (60–120 mM peptide) as well as keratinocytes (up to
60 mM peptide) in plasma and serum conditions, respectively
(Figure S5). In order to investigate a possible in vivo function of
GKY25, we therefore injected this peptide subcutaneously into
mice infected intraperitoneally with P. aeruginosa. Compared to the
controls, treatment with GKY25 yielded a significant increase in
survival (Figure 4F) and significantly lower bacterial numbers in
the spleen and kidney of the animals (Figure 4G). Taken together,
these results demonstrate that TCPs constitute a previously
undisclosed neo-structure of thrombin, formed in vitro as well as
ex vivo in plasma, but also in vivo in human wound fluid and fibrin,
exerting antimicrobial activities at physiological concentrations in
plasma, and finally, showing significant therapeutic potential.
Immunomodulatory roles of TCPs
As mentioned above, recent evidence shows that HDPs trigger
a range of immunomodulatory responses. The observation of
LPS-binding of TCPs (Figure 2D), prompted us to investigate
possible endotoxin-neutralizing effects of the model peptide
GKY25. Slot-binding experiments showed that the peptides
bound heparin as well as LPS from E. coli and P. aeruginosa
(Figure 5A). In a mouse macrophage model, GKY25 significantly
inhibited NO-release of LPS-stimulated macrophages (Figure 5B),
as well as release of TNF-a at concentrations below 2 mM (Figure
S6). Similar effects on TNF-a were noted using human
monocyte-derived macrophages (not shown). In a mouse model
of LPS-induced shock, GKY25 displayed a dramatic improve-
ment on survival (Figure 5C). Analyses of cytokines 6 hours after
LPS injection, showed significant reductions of proinflammatory
IL-6, IFN-c,T N F - a, and IL-12p70, whereas IL-10 remained
unchanged (Figure 5D). SEM analyses of lungs from LPS-treated
animals demonstrated pulmonary leakage of protein and red
blood cells (see inset in Figure 5E), an effect completely blocked
by GKY25 (Figure 5E). The results thus demonstrate that
GKY25, like many HDPs, is multifunctional; in addition to its
antimicrobial activity it also exerts potent anti-endotoxic and
immunomodulatory effects.
Functional and structural studies of thrombin-derived
C-terminal peptides
To examine possible peptide-induced permeabilization of
bacterial plasma membranes, P. aeruginosa and S. aureus was
incubated with GKY25 at concentrations yielding complete
bacterial killing (30 mM), and analyzed by electron microscopy
(Figure 6A). Clear differences in morphology between peptide-
treated bacteria and the control were demonstrated. The peptide
caused local perturbations and breaks along P. aeruginosa and S.
aureus plasma membranes, and intracellular material was found
extracellularly. These findings were similar to those seen after
treatment with LL-37 (Figure 6A). The data suggest that GKY25
acts on bacterial membranes, but do not demonstrate the exact
mechanistic events following peptide addition to bacteria, as
secondary metabolic effects on bacteria may also trigger bacterial
death and membrane destabilization. However, analogous results
were also obtained using the impermeant dye FITC and E. coli as
test bacterium (Figure 6B) demonstrating membrane permeabili-
sation after exposure to GKY25. Kinetic studies showed that
GKY25 killed .90% of bacteria after 10 minutes, compatible
with a direct action on bacterial membranes (Figure S7).
Furthermore, circular dichroism (CD) spectroscopy was used to
study the structure and the organization of the peptides GKY25
and VFR17 in solution and on interaction with negatively charged
(bacteria-like) liposomes as well as E. coli LPS. Neither GKY25 nor
VFR17 adopted an ordered conformation in aqueous solution,
however the CD spectra revealed significant structural change,
largely induction of helicity, taking place in the presence of
negatively charged liposomes (Figure 6C), and E. coli LPS
(Figure 6D). Compatible with earlier results, LL-37 displayed
some helicity also in buffer solution [26]. Similarly to LL-37, the
two thrombin-derived peptides induced leakage of liposomes, also
at high ionic strength (Figure 6E). Kinetic analysis showed that
,80% of the maximum leakage was reached within ,200 seconds
for the two thrombin-derived peptides (at 1 mM) (not shown).
Considering the above results with GKY25 and VFR17, both
containing the crucial helical (and antimicrobial) epitope, the
results therefore indicate that TCPs function like most helical
AMPs such as LL-37 [5,27], by interactions with both the lipid
GKY25 suppresses bacterial dissemination to the spleen and kidney. Mice were infected as above, GKY25 was administrated subcutaneously after 1 h,
and the cfu of P. aeruginosa in spleen and kidney was determined after a time period of 8 h (n=10 for controls and treated, P,0.05 for spleen and
kidney. Horizontal line indicates median value).
doi:10.1371/journal.ppat.1000857.g004
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surfaces, leading to induction of an a-helical conformation, which
in turn facilitates membrane interactions, membrane destabiliza-
tion, and bacterial killing.
The TCP structure complies with a c-core motif and is
evolutionary conserved
Recently, a multidimensional signature, the c-core motif, was
identified in multiple classes of cystein-containing AMPs [28].
Analysis showed that the 96aa TCP is closely related to this
fundamental motif so common in various HDPs (Figure S8).
Furthermore, this region of thrombin is highly conserved in
various species (Figure S9). Next, we compared the antibacterial
activities of C-terminal peptide GKY25 of thrombin with
corresponding peptides from other closely related human
coagulation factors (Figure 6F, for sequences see Table S3
available online). Whereas the peptide from thrombin (Factor
II), as well as peptides from factors X and IX were antimicrobial
against Gram-negative P. aeruginosa and E. coli, Gram-positive S.
aureus and B. subtilis, as well as the fungus C. albicans (Figure 6F),
corresponding peptides from factor XI and kallikrein were inactive
against these microbes (not shown). As seen in the 3D model
(Figure 6G), the coagulation factors (II, X, IX) share a similar
overall structure with a helical C-terminal ‘‘tail’’. Indeed, C-
terminals of these factors, as well as factor XI and kallikrein,
contain a pattern sequence {DS}-X-[PFY]-G-[FIV]-Y-T-X-V-
{C}-[AEQRY]-X-{R}-X-W-[IL]-X-{H}-X(4,24), which describes
an amphipathic structure. However, only factors II, X, IX have
a positive net charge (+3 or more) in this region (Table S3
available online), thus in perfect agreement with the data
obtained on the antimicrobial activity (Figure 6F). Taken
together, these analyses show that the TCP molecule represents
a novel structural entity, which is related to other cysteine-linked
HDPs containing the c-core motif, and also found in closely
related coagulation factors.
Discussion
The key finding in this report is the discovery of a novel function
of thrombin-derived C-terminal peptides in host defense. The
findings expand the field of innate immunity to thrombin and the
coagulation system. From an evolutionary perspective, this
function of thrombin is logical, since injury and infection both
represent situations necessitating an optimized innate immune
system. Hence, from the perspective of wounding, thrombin, after
fulfilling its primary function in generating a first line of defense,
the fibrin clot, adds expanded functionality this natural physical
shield by subsequent generation of antimicrobial and anti-
endotoxic HDPs upon proteolysis. The significant and curative
effect of a thrombin-derived peptide in a model of LPS-induced
shock underscores the anti-inflammatory role this novel peptide,
Figure 5. LPS-binding and immunomodulatory role in vitro and in vivo of thrombin-derived C-terminal peptides. (A) GKY25 binds
heparin and LPS. 2 and 5 mg GKY25 were applied to nitrocellulose membranes. These membranes were then blocked in PBS (containing 2% bovine
serum albumin) for 1 h at room temperature and incubated in PBS with iodinated (
125I) heparin or LPS. Unlabeled heparin (6 mg/ml) (+) was added for
competition of binding. LL-37 was used for comparison. The membranes were washed (3610 min in PBS). A Bas 2000 radioimaging system (Fuji) was
used for visualization of radioactivity. (B) GKY25 inhibits NO production. RAW264.7 macrophages were stimulated with LPS from E. coli and P.
aeruginosa, in presence of GKY25 at the indicated concentrations. LL-37 is presented for comparison. (C) GKY25 significantly increases survival in LPS-
induced shock. Mice were injected with LPS followed by intraperitoneal administration of GKY25 (200 mg). Survival was followed for 7 days. (n=9 for
controls, n=10 for treated animals, P,0.001). (D) GKY25 attenuates proinflammatory cytokines. In a separate experiment, mice were sacrificed 6 h after
i.p. injection of LPS followed by treatment with GKY25 (200 mg) or buffer, and the indicated cytokines were analyzed in blood (n=9 for controls, n=10
for treated animals, the P values for the respective cytokines are IL-6, 0.001; IFN-c=0.009; TNF, 0.001; IL-12p70, 0.001. IL-10 was not significant.). (E)
Lungs were analyzed by scanning electron microscopy 20 h after LPS injection i.p., followed by treatment with GKY25 (200 mg) or buffer. Treatment
with the peptides blocked leakage of proteins and erythrocytes (see inset) (n=3 in both groups, and a representative lung section is shown).
doi:10.1371/journal.ppat.1000857.g005
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as the anaphylatoxin C3a and chemotactic defensins [14,29].
Thus, during injury and infection, different pathways are
activated, employing HDPs with multiple and sometimes opposite
roles, all balancing and fine-tuning inflammation while counter-
acting microbial invasion. Recent evidence showing a significant
cross-talk between the coagulation and complement systems [30]
further adds biological relevance to the observed generation of
C3a and various TCPs during inflammation.
TCPs further add to the increasingly recognized redundancy of
host defense mechanisms, enforcing optimized control of the
microbial flora by minimizing the risk for resistance development
against one particular HDP, as well as protecting against
detrimental effects due to specific HDP deficiencies. Notably, the
Figure 6. Mode of action of thrombin-derived C-terminal peptides. (A) Electron microscopy analysis. P. aeruginosa and S. aureus bacteria was
incubated for 2 h at 37uC with 30 mM of GKY25 and LL-37 and analyzed with electron microscopy. Scale bar represents 1 mm. Control; Buffer control.
(B) Permeabilizing effects of peptides on E. coli. Bacteria were incubated with the indicated peptides at 30 mM and permeabilization was assessed
using the impermeant probe FITC. (C) Helical content of the thrombin-derived C-terminal peptides GKY25 and VFR17 in presence of negatively
charged liposomes (PA). The two peptides showed a marked helix induction upon addition of the liposomes. (D) CD spectra of GKY25 and VFR17 in
Tris-buffer and in presence of LPS. For control, CD spectra for buffer and LPS alone are also presented. (E) Effects of the indicated peptides on
liposome leakage. The membrane permeabilizing effect was recorded by measuring fluorescence release of carboxyfluorescein from PA (negatively
charged) liposomes. The experiments were performed in 10 mM Tris-buffer, in absence and presence of 0.15 M NaCl. Values represents mean of
triplicate samples. (F) Activities of corresponding C-terminal peptides of the indicated coagulation factors. Peptides were tested in RDA against the
indicated bacteria. Bacteria (4610
6 cfu) were inoculated in 0.1% TSB agarose gels. Each 4 mm-diameter well was loaded with 6 ml of peptide at
100 mM. The zones of clearance correspond to the inhibitory effect of each peptide after incubation at 37uC for 18–24 h. (G) Overlay 3D-model
showing the three coagulation factors thrombin, and factor X and IX. The C-terminal parts are indicated.
doi:10.1371/journal.ppat.1000857.g006
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different lengths parallel previous findings on LL-37 and C3a
[14,31], showing that these molecules are further processed while
retaining their antimicrobial activity. Although not shown in this
study, additional HDPs may be released from C-termini of factor
X and XI, further increasing the arsenal of HDPs and adding to
redundancy. From an investigatory standpoint, such concerted
action is challenging when it comes to defining roles of a given
peptide in vivo. Nevertheless, the suppressive effects of formed
TCPs on bacterial growth ex vivo, their association with bacterial
surfaces ex vivo and in vivo, as well as significant effects of the TCP
GKY25 under standard NCSLA conditions, as well as in an
animal model of P. aeruginosa sepsis, clearly indicate an in vivo role
for released TCPs. These findings, in concert with the anti-
endotoxic and immunomodulatory effects of the peptides in vitro
and in vivo, infer interesting therapeutic possibilities for TCPs in
treatment of local and systemic infections, as well as sepsis. Recent
evidence, showing a higher susceptibility to S. aureus infection in
mice rendered thrombin-deficient [32], is also compatible with the
new role in host-defense of thrombin-derived C-terminal peptides
revealed here. Of relevance is also the increased susceptibility to
infection after inhibition of the contact system, linked to abrogated
release of kininogen-derived HDPs [16], but possibly also due to a
reduced capability to form TCPs and other antimicrobial
molecules associated with fibrin networks. Of particular clinical
relevance is also the finding that TCPs are detected in wound
fluids from patients with acute surgical wounds, as well as in
patients with non-healing wounds. The latter patient group is
characterized by an excessive bacterial colonization e.g. by P.
aeruginosa, extensive proteolysis and inflammation [24]. Although
speculative, the noted absence of TCPs in some patients could
therefore be indicative of a defective host-defense and diminished
control of released endotoxins (local or systemic). Thus, apart from
therapeutic possibilities, the present findings provide a potential
diagnostic marker for inflammation, which is currently under
evaluation in larger patient groups. Concerning the immunomod-
ulatory role of TCPs, it should be noted that although a direct
binding and thus inhibition of LPS activity was demonstrated, the
observed anti-inflammatory effects could also depend on addi-
tional effects by TCPs on various intracellular signaling pathways
including inhibition of NF-kB activation.
From a structural standpoint, the TCP structure relates to the
previously reported c-core signature that characterize many
cysteine-containing AMPs [28], further supporting the concept
of multidimensional signatures in antimicrobial peptides and
extending these also to HDPs of coagulation factors. The high
degree of conservation of the cysteine-constrained TCP-molecule
during evolution also suggests that the TCP structure is, although
novel to science, not necessarily new. Interestingly, the 96-amino
acid TCP also contains a peptide region responsible for the well-
known growth promoting activity of thrombin [33], further adding
biological importance to the findings. It remains to be investigated
whether thrombin fragments comprising this region promote cell-
growth. If so, these TCPs, generated in response to injury mediate
not only microbial evasion and immunomodulation, but also
wound closure, three fundamental aspects of host defense.
Materials and Methods
Ethics statement
The use of human wound materials was approved by the Ethics
Committee at Lund University (LU 708-01, LU 509-01). Written
informed consent was obtained from the participants. The animal
experiments were conducted according to national guidelines
(Swedish Animal Welfare Act SFS 1988:534), and were approved
by the Laboratory Animal Ethics Committee of Malmo ¨/Lund.
Peptides and proteins
Prothrombin and thrombin were from Innovative Research,
USA. The coagulation factor-derived peptides (Table S3) and
omiganan (ILRWPWWPWRRK-amide) were synthesized by Bio-
peptide Co. The purity (.95%) and molecular weight of these
peptides was confirmed by mass spectral analysis (MALDI.TOF
Voyager). LL-37 (LLGDFFRKSKEKIGKEFKRIVQRIKDFLRN-
LVPRTES) was from Innovagen AB. 20mer peptides corresponding
to various overlapping regions of prothrombin (Figure 2) were from
Sigma (Custom Peptide Libraries, SigmaGenosys).
Biological materials
Wound fluids (100–600 ml) from patients with chronic venous
leg ulcers were collected under a Tegaderm dressing for 2 h as
previously described [25]. Fibrin slough from two chronic venous
leg ulcers (chronic wound slough/surface, denoted CWS) was
collected by a sterile spatula, and was immediately put into the fix
solution for electron microscopy. Sterile wound fluids were
obtained from surgical drainages after mastectomy. Collection
was for 24 h, 24 to 48 h after surgery. Wound fluids were
centrifuged, aliquoted and stored at 220uC.
Microorganisms
Escherichia coli ATCC 25922, Pseudomonas aeruginosa ATCC
27853, Pseudomonas aeruginosa 15159, Staphylococcus aureus ATCC
29213, Bacillus subtilis ATCC 6633 bacterial isolates, and the
fungal isolate Candida albicans ATCC 90028 were from the
Department of Bacteriology, Lund University Hospital.
Radial diffusion assay
Essentially as described earlier [34,35], bacteria were grown to
mid-logarithmic phase in 10 ml of full-strength (3% w/v) trypti-
case soy broth (TSB) (Becton-Dickinson). The microorganisms
were then washed once with 10 mM Tris, pH 7.4. Subsequently,
4610
6 cfu were added to 15 ml of the underlay agarose gel,
consisting of 0.03% (w/v) TSB, 1% (w/v) low electroendosmosis
type (EEO) agarose (Sigma-Aldrich) and 0.02% (v/v) Tween 20
(Sigma-Aldrich). The underlay was poured into a Ø 144 mm petri
dish. After agarose solidification, 4 mm-diameter wells were
punched and 6 ml peptide solution of required concentration
added to each well. Plates were incubated at 37uC for 3 h to allow
peptide diffusion. The underlay gel was then covered with 15 ml
of molten overlay (6% TSB and 1% Low-EEO agarose in distilled
H2O). Antimicrobial activity of a peptide was visualized as a zone
of clearing around each well after 18–24 h of incubation at 37uC.
Viable count assays and analysis of bacterial growth
E. coli ATCC 25922 bacteria were grown to mid-logarithmic
phase in Todd-Hewitt (TH) medium. Bacteria were washed and
re-suspended in 10 mM Tris, pH 7.4 containing 5 mM glucose. E.
coli ATCC 25922 (50 ml; 2610
6 cfu/ml) were incubated, at 37uC
for 2 h with prothrombin, thrombin, GKY25, or VFR17 at 3 and
6 mM. For assessment of bacterial growth in plasma and effect of
TCPs, overnight cultures (in TH) of P. aeruginosa 15159 and S.
aureus ATCC 29213 bacteria were incubated (17 ml in 450 ml) with
control plasma, acute wound fluid (AWF) or depleted AWF,
plasma depleted of prothrombin (DP, Innovative Research), or DP
supplemented with the peptide GKY25 (at 1.5 mM) for 0, 2, 4, and
6 h at 37uC. Serial dilutions of the incubation mixtures were
plated on TH agar, followed by incubation at 37uC overnight and
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of thrombin and fragments containing C-terminal peptides, AWF
was diluted with an equal volume of PBS, and passaged 5 times
through an affinity column (0.3 ml, Thermo Scientific) having
coupled IgG antibodies specific for VFR17 (Innovagen AB). For
control, a column with rabbit IgG was used.
Flow cytometry analysis
50 ml of overnight bacteria was added to 450 ml of human
plasma, AWF, or DP either alone or supplemented with the
peptide GKY25 (at 1.5 mM). Samples were incubated for 4 h at
37uC, centrifuged, washed with PBS, resuspended in 100 ml PBS
with polyclonal antibodies against VFR17 (1:100), and subse-
quently incubated for one hour at room temperature. Bacteria
were pelleted and washed twice with PBS, incubated in 100 ml
PBS with goat anti rabbit IgG FITC-labeled antibodies (1:500,
Sigma) for 30 min at room temperature and washed twice with
PBS. Flow cytometry analysis (Becton-Dickinson, Franklin Lakes,
NJ) was performed using a FACS-Calibur flow cytometry system
equipped with a 15 mW argon laser turned a 488 nm. The
bacterial population was selected by gating with appropriate
settings of forward scatter (FSC) and sideward scatter (SSC).
Slot-blot assay
LPS-binding ability of the peptides was examined by a slot-blot
assay. Peptides (2 and 5 mg) were bound to nitrocellulose
membranes (Hybond-C, GE Healthcare BioSciences), pre-soaked
in PBS. Membranes were then blocked by 2 wt% BSA in PBS,
pH 7.4, for 1 h at room temperature, and subsequently incubated
with
125I-labeled LPS (40 mg/ml; 0.13610
6 cpm/mg) for 1 h in
PBS. After incubation, the membranes were washed 3 times,
10 min each time, in PBS and visualized for radioactivity on Bas
2000 radioimaging system (Fuji). Unlabeled heparin (6 mg/ml)
was added for competition of binding.
Liposome preparation and leakage assay
Dry lipid films were prepared by dissolving either dioleoylpho-
sphatidylethanolamine (Avanti Polar Lipids, Alabaster, AL)
(70 mol%) and dioleoylphosphatidylglycerol (30 mol%) in chloro-
form, and then removing the solvent by evaporation under
vacuum overnight. Subsequently, buffer solution containing
10 mM Tris, pH 7.4, either with or without additional 150 mM
NaCl, was added together with 0.1 M carboxyfluorescein (CF)
(Sigma). After hydration, the lipid mixture was subjected to eight
freeze-thaw cycles consisting of freezing in liquid nitrogen and
heating to 60uC. Unilamellar liposomes with a diameter of about
130 nm (as found with cryo-TEM; results not shown) were
generated by multiple extrusions through polycarbonate filters
(pore size 100 nm) mounted in a LipoFast miniextruder (Avestin).
Untrapped carboxyfluorescein was then removed by filtration
through two subsequent Sephadex G-50 columns with the relevant
Tris buffer as eluent. Both extrusion and filtration was performed
at 22uC. The CF release was monitored by fluorescence at 520 nm
from a liposome dispersion (10 mM lipid in 10 mM Tris pH 7.4).
An absolute leakage scale is obtained by disrupting the liposomes
at the end of the experiment through addition of 0.8 mM Triton
6100 (Sigma), thereby causing 100% release and dequenching of
CF. A SPEX-fluorolog 1650 0.22-m double spectrometer (SPEX
Industries) was used for the liposome leakage assay.
CD-spectroscopy
Circular dichroism (CD) spectra were measured by a Jasco J-
810 Spectropolarimeter (Jasco, Easton, USA). The measurements
were performed in triplicate at 37uC in a 10 mm quartz cuvette
under stirring with a peptide concentration of 10 mM. The effect
on peptide secondary structure of liposomes at a lipid concentra-
tion of 100 mM, and of E. coli LPS at a concentration of 0.02 wt%,
was monitored in the range 200–250 nm. To account for
instrumental differences between measurements, the background
value (detected at 250 nm, where no peptide signal is present) was
subtracted. Signals from the bulk solution were also corrected for.
Fluorescence microscopy
For study of membrane permeabilization using the impermeant
probe FITC, E. coli ATCC 25922 bacteria were grown to mid-
logarithmic phase in TSB medium. The bacteria were washed and
resuspended in either 10 mM Tris, pH 7.4, 10 mM glucose, to
yield a suspension of 1610
7 cfu/ml. 100 ml of the bacterial
suspension was incubated with 30 mM of the respective peptides at
30uC for 30 min. Microorganisms were then immobilized on poly
(L-lysine)–coated glass slides by incubation for 45 min at 30uC,
followed by addition onto the slides of 200 ml of FITC (6 mg/ml) in
the appropriate buffers and incubated for 30 min at 30uC. The
slides were washed and bacteria fixed by incubation, first on ice for
15 min, then in room temperature for 45 min in 4% paraformal-
dehyde. The glass slides were subsequently mounted on slides
using Prolong Gold antifade reagent mounting medium (Invitro-
gen). For fluorescence analysis, bacteria and fungi were visualized
using a Nikon Eclipse TE300 (Nikon, Melville, NY) inverted
fluorescence microscope equipped with a Hamamatsu C4742-95
cooled CCD camera (Hamamatsu) and a Plan Apochromat 6100
objective (Olympus, Orangeburg, NY). Differential interference
contrast (Nomarski) imaging was used for visualization of the
microbes themselves.
Electron microscopy
For transmission electron microscopy and visualization of
peptide effects on bacteria, P. aeruginosa ATCC 27853 and S.
aureus ATCC 29213 (1–2610
6 cfu/sample) were incubated for 2 h
at 37uC with the peptide GKY25 at 30 mM. LL-37 (30 mM) was
included as a control. Samples of P. aeruginosa and S. aureus
suspensions were adsorbed onto carbon-coated copper grids for
2 min, washed briefly on two drops of water, and negatively
stained on two drops of 0.75% uranyl formate. The grids were
rendered hydrophilic by glow discharge at low pressure in air. For
analysis of effects on biological fluids on bacterial integrity as well
as detection of bound TCPs, P. aeruginosa 15159 bacteria, grown
overnight in TH, were washed and resuspened in PBS (1610
9 cfu/
ml). Equal volumes of bacterial suspension and chronic wound
fluids were incubated together for 30 min at 37uC. For control,
2 mM of GKY25 was incubated with bacteria for 30 min at 37uC.
In another experiment, P. aeruginosa 15159 bacteria were directly
added to citrate plasma or AWF in the absence or presence of
heparin (100 mg/ml), and further incubated for 4 h at 37uC. All
the samples were centrifuged and washed with PBS and re-
suspended in 4% paraformaldehyde and stored at 4uC, followed
by gold labeling. Fibrin slough from patients with chronic venous
ulcers (CWS) was fixed (1.5% PFA, 0.5% GA in 0.1 M phosphate
buffer, pH 7.4) for 1 h at room temperature, followed by washing
with 0.1 M phosphate buffer, pH 7.4. The fixed and washed
samples were subsequently dehydrated in ethanol and further
processed for Lowicryl embedding [36]. Sections were cut with a
LKB ultratome and mounted on gold grids. For immunostaining,
the grids were floated on top of drops of immune reagents
displayed on a sheet of parafilm. Free aldehyde groups were
blocked with 50 mM glycine, and the grids were then incubated
with 5% (vol/vol) goat serum in incubation buffer (0.2% BSA-c in
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followed by overnight incubation with 1 mg/ml of VFR17
polyclonal antibodies at 4uC. Controls without these primary
antibodies were included. After washing the grids in a large
volume (200 ml) of incubation buffer, floating on drops containing
the gold conjugate reagents, 1 mg/ml EM goat antiRabbit IgG
10nm Au (BBI) in incubation buffer was performed for 2 h at 4uC.
After further washes by an excess volume of incubation buffer, the
sections were postfixed in 2% glutaraldehyde. Finally, sections
were washed with distilled water and poststained with 2% uranyl
acetate and lead citrate. All samples were examined with a Jeol
JEM 1230 electron microscope operated at 80 kV accelerating
voltage. Images were recorded with a Gatan Multiscan 791
charge-coupled device camera.
Degradation of prothrombin and thrombin
Prothrombin and thrombin (Innovative Research) (27 mg,
0.6 mg/ml) was incubated at 37uC with human neutrophil
elastase (NE) (0.6 mg, 20 units/mg) (Sigma) and prothrombin also
with cathepsin G (0.5 mg, 2 units/mg) (BioCol GmbH) or P.
aeruginosa elastase (PAE) (30 mU, a generous gift from Dr. H.
Maeda, Kumamoto University, Japan) in a total volume of 45 ml
10 mM Tris, pH 7.4 for different time periods as indicated in the
figures. Neutrophils were prepared by routine procedures (Poly-
morphprep) from blood obtained from healthy human donors.
The cells were disrupted by freeze-thawing and addition of 0.3%
Tween 20. Neutrophil extracts (corresponding to 4.8610
7 cells)
were incubated at 37u with thrombin (27 mg, 0.6 mg/ml) for
180 min. The reaction was stopped by boiling at 95uC for 3 min.
6 ml (3.6 mg) of the material was analyzed by RDA and 20 ml
(12 mg) fractions analyzed by SDS-PAGE using 16.5% precast
Tris-tricine gels (Bio-rad), run under non-reducing or reducing
conditions. The gels were stained with Coomassie brilliant blue
and destained.
Definition of cleavage products of thrombin
Peptide fragments of thrombin, digested by neutrophil elastase
for 30 min, were separated by hplc (PerkinElmer Series 200) on a
reversed phase column (Vydac 218TPC18, 25064.6 mm, 5 mm)
(Dalco chromtech AB). After injection, samples were eluted with a
gradient of acetonitrile in 0.1% aqueous trifluroacetic acid at 1 ml
per minute. Fractions were collected and stored at 280uC.
Samples were freeze-dried, redissolved in water, and analyzed by
RDA, SDS-PAGE, immunoblotting and gel-overlay assay
(Figure 3). Active fractions were analyzed by combinations of
MALDI-TOF MS, ESI-MS/MS, N- and C-terminal sequencing
at the Karolinska Institutet Protein Analysis Center (PAC
Stockholm). See also legend to Figure 3 for additional information.
SDS-PAGE and immunoblotting
Prothrombin and thrombin, either intact or subjected to
enzymes, were analyzed by SDS-PAGE on 16.5% Tris-tricine
gels (Bio-Rad). Proteins and peptides were transferred to
nitrocellulose membranes (Hybond-C). Membranes were blocked
by 3% (w/v) skimmed milk, washed, and incubated for 1 h with
rabbit polyclonal antibodies recognizing the peptide VFR17
(1:800) (Innovagen AB) or rabbit antibodies of similar specificity
(1:1000) (Dako), washed three times for 10 min, and subsequently
incubated (1 h) with HRP-conjugated secondary antibodies
(1:2000) (Dako), and then washed again three times, each time
for 10 min. C-terminal thrombin peptides were visualized by an
enhanced chemiluminesent substrate (LumiGLOH) developing
system (Upstate cell signaling solutions). For identification of TCPs
in human fibrin, normal citrate-plasma was supplemented with
10 mM Ca
2+ in eppendorf tubes at 37uC overnight. The clots
formed were washed three times with PBS and incubated with
human neutrophil elastase (20 units/mg) for 0, 1, and 3 h at 37uC.
Samples were centrifuged at 10000 RPM for 10 min, after which
supernatants and pellets were separated. Samples were freeze-
dried and then redissolved in 60% acetonitrile and 0.1% aqueous
TFA. Pooled samples were freeze-dried, redissolved in water and
analyzed by SDS-PAGE followed by immunoblotting as above.
For identification of TCPs in human citrate plasma, 1.5 mlo f
citrate-plasma or patient would fluids were analysed by SDS-
PAGE under reducing conditions, followed by immunoblotting as
above. For identification of TCPs bound to bacteria, overnight
cultures of P. aeruginosa 15159 bacteria were washed, resuspended,
and incubated with human plasma or a preformed fibrin clot [37]
for 4 h at 37uC. The bacterial cells were collected, washed wih
PBS, and bound proteins were eluted with 0.1 M glycine-HCL,
pH 2.0. The pH of the eluted material was raised to 7.5 with the
addition of 1 M Tris. Eluted proteins were precipitated with 5%
trichloroacetic acid (TCA) for 30 min on ice followed by
centrifugation at 15 000g (4uC for 20 min). Precipitated material
was dissolved in SDS sample buffer and subjected to Tris-Tricine
SDS-PAGE under reducing conditions, followed by immunoblot-
ting as above.
Gel-overlay assay
Gel overlay assay was performed essentially as described
previously [35]. Briefly, duplicate samples were run on non-
denaturing acid urea (AU-PAGE) gels in 5% acetic acid at 100 V
for 1 h 15 min. Bacteria were grown overnight in TH broth,
inoculated, and grown until the OD was 0.4. The bacteria were
washed and resuspended in 10 mM Tris, pH 7.4. Bacteria (4610
6)
w e r ea d d e dt o1 2 m lm e l t e du n d e r l a ya g a r o s e( 1 0 m MT r i s ,
pH 7.4, 0.03% TH broth, 1% agarose type 1 (Sigma-Aldrich)) and
poured into a square petri dish. One AU gel was stained with
Coomassie brilliant blue and one AU gel was washed three times for
4 min in 10 mM Tris, pH 7.4 and then placed on top of the
agarose gel and incubated for 3 h at 37uC. The AU gel was then
removed and an overlay agarose (6% TH broth, 1% agarose type 1)
was poured on top of the underlay and incubated overnight at 37uC.
To make the clearing zones more visible, the agarose was stained
with Coomassie brilliant blue and then destained with water.
Animal infection model
Animals were housed under standard conditions of light and
temperature and had free access to standard laboratory chow and
water. P. aeruginosa 15159 bacteria were grown overnight,
harvested, washed in PBS, diluted in the same buffer to 2610
8
cfu/ml, and kept on ice until injection. Hundred microliter of the
bacterial suspension were injected intraperitoneally (ip) into female
BALB/c mice. Sixty minutes after the bacterial injection, 0.5 mg
GKY25 or buffer alone was injected sc into the mice. This was
repeated after 24 hours. In this Pseudomonas infection model,
infected mice develop severe signs of sepsis within 1–2 days and
usually do not recover from the infection. In order to study
bacterial dissemination to target organs, the mice were infected as
previously described and after a time period of 8 h, spleen and
kidney were harvested, placed on ice, homogenized, and colony-
forming units determined. The P-value was determined using the
Mann-Whitney U-test. Data from three independent experiments
were pooled.
LPS effects on macrophages in vitro
3.5610
5 cells were seeded in 96-well tissue culture plates (Nunc,
167008) in phenol red-free DMEM (Gibco) supplemented with
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adherence, cells were stimulated with 100 or 10 ng/mL E. coli
(0111:B4) or P. aeruginosa LPS (Sigma), with and without peptide of
various doses. The levels of NO in culture supernatants were
determined after 24 hours from stimulation using the Griess
reaction [38]. Briefly, nitrite, a stable product of NO degradation,
was measured by mixing 50 ml of culture supernatants with the
same volume of Griess reagent (Sigma, G4410) and reading
absorbance at 550 nm after 15 min. Phenol-red free DMEM with
FBS and antibiotics were used as a blank. A standard curve was
prepared using 0–80 mM sodium nitrite solutions in ddH20.
LPS model in vivo
C57BL/6 mice (8–10 weeks, 22+/25g), divided into weight and
sex matched groups, were injected intraperitoneally with 18 mg E.
coli 0111:B4 LPS (Sigma) per kg of body weight. Thirty minutes
after LPS injection, 0.2 mg GKY25 or buffer alone was injected
intraperitoneally into the mice. Survival and status was followed
during seven days. For the cytokine assay, mice were sacrificed 6 h
post LPS challenge, and blood was collected by cardiac puncture.
For SEM, mice were sacrificed 20 h after LPS challenge, and
lungs were removed and fixed.
Cytokine assay
The cytokines IL-6, IL-10, MCP-1, INF-c, TNF-a, and IL-
12p70 were measured in plasma from LPS-infected mice (with or
without GKY25 treatment) using the Cytometric bead array;
mouse inflammation kit (Becton Dickinson AB) according to the
manufacturer’s instructions.
Statistical analysis
Bar diagrams (RDA, VCA) are presented as mean and standard
deviation, from at least three independent experiments. Animal
data are presented as dot plots, with mean for normally distributed
data, or median for data, which do not meet the criteria for
normal distribution. Outliers were not excluded from the statistical
analysis. Differences with P,0.05 were considered statistically
significant.
MIC, hemolysis, MTT, and LDH assay
MIC assay was carried out by a microtiter broth dilution
method as previously described in the NCSLA guidelines [39].
Hemolysis, MTT, and LDH assays were performed as previously
described [40] (See Text S1).
Alignment of TCPs
See Text S1.
Supporting Information
Text S1 Methods
Found at: doi:10.1371/journal.ppat.1000857.s001 (0.03 MB
DOC)
Figure S1 Antimicrobial activities. Activities of peptides (RDA)
of prothrombin-derived peptides against P. aeruginosa in absence
and presence of 0.1 M NaCl, and against E. coli in 0.1 M NaCl.
Each 4 mm-diameter well was loaded with 6 ml of the solution.
The bar diagrams indicate the zones of clearance obtained (in
mm).
Found at: doi:10.1371/journal.ppat.1000857.s002 (0.54 MB TIF)
Figure S2 TCPs are formed and bind to and inhibit microbes in
plasma environment. (A) Overnight cultures of P. aeruginosa 15159
bacteria were washed, resuspended, and incubated with citrate
plasma or a preformed fibrin clot for 4 h at 37uC. The bacterial
cells were collected, washed with PBS, and bound proteins and
corresponding supernatants were subjected to Tris-Tricine SDS-
PAGE under reducing conditions, followed by immunoblotting
with antibodies recognizing the C-terminal part of thrombin. 1
and 2, unbound and bound material in plasma; 3 and 4, unbound
and bound material after incubation with fibrin. (B) Flow
cytometry analysis of binding of C-terminal thrombin epitopes
to S. aureus bacteria. Bacteria were incubated for 4 h with control
plasma (P), human plasma depleted of prothrombin (DP), depleted
plasma supplemented with the peptide GKY25, or, acute wound
fluid (AWF). Binding of C-terminal epitopes to the bacteria was
detected using primary antibodies against the C-terminal epitope
VFR17 followed by addition of FITC-labeled secondary antibod-
ies. Absence of detectable binding of FITC-labeled secondary
antibodies to S. aureus in prothrombin-depleted plasma, excludes
any significant influence of unspecific Protein A based interactions
in this experimental system. Likewise, FITC-labeled antibodies
alone did not show any significant unspecific binding. (C) TCPs
inhibit growth of S. aureus in human plasma. Similarly as in
Figure 4E, control plasma (P), plasma depleted of prothrombin
(DP), depleted plasma supplemented with either prothrombin
(DP+PT), or GKY25 (DP+GKY25) (both at 1.5 mM) were
inoculated with S. aureus bacteria. The multiplication factors at
various time points are given. After incubation, CFUs were
determined by plating. Experiments were repeated three times and
a representative experiment is shown.
Found at: doi:10.1371/journal.ppat.1000857.s003 (2.48 MB TIF)
Figure S3 TCPs bind and damage bacteria. Visualization of
binding and membrane damage by TCPs. P. aeruginosa bacteria
alone (Control) or after incubation with 1.5 mM of GKY25, were
analyzed by electron microscopy following negative staining.
P+Hep and AWF+Hep indicate the results obtained after addition
of 100 mg/ml heparin during the incubation with human plasma
and acute wound fluid, respectively. Absence of TCPs at bacterial
surfaces as well as membrane damage was noted in the heparin-
treated material. Examination of at least 50 different bacterial
profiles demonstrated a significant difference between immuno-
gold binding in P and AWF sections and corresponding material
with heparin. Thus .80% of gold particles were associated with
bacterial surfaces in P and AWF, whereas the material
supplemented with heparin contained a low background of
particles distributed unspecifically.
Found at: doi:10.1371/journal.ppat.1000857.s004 (9.78 MB TIF)
Figure S4 TCPs are found in human wounds. Visualization of
binding of TCPs to cocci found in fibrin slough from a chronic
wound surface (CWS-1 and -2) of two patients with S. aureus
infected chronic leg ulcers. In the EM experiments, no significant
unspecific binding of gold-conjugated IgG was observed. Scale
bar; 200 nm.
Found at: doi:10.1371/journal.ppat.1000857.s005 (10.22 MB
TIF)
Figure S5 Effects on eukaryotic cells. (A) Hemolytic effects of
GKY25 in blood (EDTA-blood made 50% with PBS) were
investigated. The cells were incubated with different concentrations
of the peptide or LL-37. 2% Triton X-100 (Sigma-Aldrich) served as
positive control. The absorbance of hemoglobin release was
measured at l 540 nm and is expressed as % of Triton X-100
induced hemolysis (note the scale of the y-axis). (B) HaCaT
keratinocytes were subjected to GKY25 and LL-37 in presence of
20%humanserum.Cellpermeabilizingeffectsweremeasuredbythe
LDHbased TOX-7 kit.LDHreleasefromthe cellswasmonitored at
l 490 nm and was plotted as % of total LDH release. (C) The MTT-
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presence of the indicated peptides. In the assay, MTT is modified
into a dye, blue formazan, by enzymes associated with metabolic
activity. The absorbance of the dye was measured at l 550 nm.
Found at: doi:10.1371/journal.ppat.1000857.s006 (1.76 MB TIF)
Figure S6 TNF-a release is inhibited by GKY25. RAW264.7
macrophages were stimulated with LPS from E. coli, in presence of
GKY25 at the indicated concentrations. LL-37 is presented for
comparison.
Found at: doi:10.1371/journal.ppat.1000857.s007 (0.69 MB TIF)
Figure S7 Kinetics of GKY25 action. E. coli bacteria were
grown to mid-logarithmic phase in Todd-Hewitt (TH) medium.
They were then washed and diluted in 10 mM Tris, pH 7.4
containing 5 mM glucose. Following this, bacteria (50 ml; 2610
6
cfu/ml) were incubated, at 37uC for for 5, 10, 20, 40, 60 and
120 min with GKY25 at 6 mM in presence of 10 mM Tris,
0.15 M NaCl, pH 7.4. To quantify the bactericidal activity, serial
dilutions of the incubation mixtures were plated on TH agar,
followed by incubation at 37uC overnight and the number of
colony-forming units was determined. 100% survival was defined
as total survival of bacteria in the same buffer and under the same
condition in the absence of peptide.
Found at: doi:10.1371/journal.ppat.1000857.s008 (0.22 MB TIF)
Figure S8 c-core motif of TCP. Cartoon representation of the
part corresponding to the C-terminal 96 amino acids of the crystal
structure of thrombin (PDB code: 1C5L, amino acids 527–622).
The region C536KDSTRIRITDNMFCAGYKP555 containing the
proposed c-core motif is indicated in red. Cysteines are indicated
in yellow and glycines in orange. The motif corrsponds to the
levomeric isoform 1 described by Yount and Yeaman (Yount,
N.Y. & Yeaman, M.R. Multidimensional signatures in antimicro-
bial peptides. Proc Natl Acad Sci U S A 101, 7363–7368 (2004));
(NH2…[C]-[X13]-[CXG]-[X2]-P…COOH), and is quite similar
to the c-core motif found in kinocidins (Yeaman, M.R & Yount,
N.Y. Unifying themes in host defence effector polypeptides. Nat
Rev Microbiol. 5, 727–740 (2007)).
Found at: doi:10.1371/journal.ppat.1000857.s009 (1.35 MB TIF)
Figure S9 Alignment of human TCP with related thrombin
sequences. The conserved cysteine residues, as well as two CXG
motifs are indicated. Arrow indicates the N-terminus of the 96
amino acid peptide generated by neutrophil elastase.
Found at: doi:10.1371/journal.ppat.1000857.s010 (7.95 MB TIF)
Table S1 Peptide sequences of fraction 20–21. Masses were
obtained by MALDI-MS analysis, and possible peptide sequences
from the prothrombin sequence were deduced using the
FINDPEPT tool (www.expasy.org/tools/findpept.html).
Found at: doi:10.1371/journal.ppat.1000857.s011 (0.03 MB
DOC)
Table S2 Minimal inhibitory concentrations (MIC) of GKY25,
LL-37 and omiganan against various bacterial isolates. The
analysis was performed as described in Wiegand et al. [39] and
according to NCSLA guidelines. Additional clinical isolates were
obtained from the Department of Bacteriology, Lund University
Hospital. P. aeruginosa, E. coli and E. faecalis isolates were initially
derived from patients with chronic ulcers, S. aureus from patients
with atopic dermatitis. The S. pyogenes strain AP1 was from the
WHO Collaborating Center for References and Research on
Streptococci (Prague, Czech Republic).
Found at: doi:10.1371/journal.ppat.1000857.s012 (0.04 MB
DOC)
Table S3 Sequences of coagulation factor-derived peptides.
Found at: doi:10.1371/journal.ppat.1000857.s013 (0.02 MB
DOC)
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